Design, Synthesis and Anticancer Profile of New 4-(1H-benzo[d]imidazol-1-yl)pyrimidin-2-amine-Linked Sulfonamide Derivatives with V600EBRAF Inhibitory Effect

• Published in: International journal of molecular sciences Vol. 22; no. 19; p. 10491
• Main Authors: Abdel-Maksoud, Mohammed S., Mohamed, Ahmed A. B., Hassan, Rasha M., Abdelgawad, Mohamed A., Chilingaryan, Garri, Selim, Samy, Abdel-Bakky, Mohamed S., Al-Sanea, Mohammad M.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2021; MDPI
• Subjects: Antibiotics; anticancer; benzimidazole; BRAF inhibitors; Cancer; Cell cycle; Fibrosarcoma; Hydrocarbons; Kinases; Melanoma; Mutation; sulfonamide; Sulfonamides; synthesis; Thyroid gland; Tumor cell lines
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms221910491

A new series of 4-(1H-benzo[d]imidazol-1-yl)pyrimidin-2-amine linked sulfonamide derivatives 12a–n was designed and synthesized according to the structure of well-established V600EBRAF inhibitors. The terminal sulfonamide moiety was linked to the pyrimidine ring via either ethylamine or propylamine bridge. The designed series was tested at fixed concentration (1 µM) against V600EBRAF, finding that 12e, 12i and 12l exhibited the strongest inhibitory activity among all target compounds and 12l had the lowest IC50 of 0.49 µM. They were further screened on NCI 60 cancer cell lines to reveal that 12e showed the most significant growth inhibition against multiple cancer cell lines. Therefore, cell cycle analysis of 12e was conducted to investigate the effect on cell cycle progression. Finally, virtual docking studies was performed to gain insights for the plausible binding modes of vemurafenib, 12i, 12e and 12l.